The clinical trial industry is, once again, at an uncertain crossroads. And while it might be assumed that the outsized impact of the COVID-19 pandemic has resulted in the inability to recruit patients for trials, it is instead, a challenge generated, over time, by the industry itself. Thankfully, there is an opportunity to change course.
It’s no secret that research studies and clinical trial sites struggle with recruitment. In fact, the National Institutes of Health (NIH) states that of all terminated clinical trials, 55 percent were terminated due to low accrual rates. In total, around 80 percent of research studies fail to meet their enrollment goals in their projected timeframes.
